Kavita Juneja
Overview
Explore the profile of Kavita Juneja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, et al.
J Infect Dis
. 2024 Apr;
230(3):624-634.
PMID: 38657001
Background: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to...
2.
Humeniuk R, Juneja K, Chen S, Ellis S, Anoshchenko O, Xiao D, et al.
Clin Transl Sci
. 2023 Sep;
16(11):2276-2288.
PMID: 37688349
Intravenous remdesivir (RDV) is US Food and Drug Administration-approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS-443902, and...
3.
Brown S, Katz M, Ginde A, Juneja K, Ramchandani M, Schiffer J, et al.
Infect Dis Ther
. 2023 Apr;
12(4):1189-1203.
PMID: 37074613
Introduction: In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients....
4.
Bauer R, Teterina A, Shivram H, McBride J, Rosenberger C, Cai F, et al.
Clin Transl Sci
. 2023 Mar;
16(6):1049-1062.
PMID: 36929625
Observational studies have identified the potential prognostic value for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load and anti-SARS-CoV-2 antibodies in coronavirus disease 2019 (COVID-19). However, viral load in nasopharyngeal...
5.
Kulkarni R, Chauhan S, Joshi B, Balsaraf K, Chaudhari R, Donde G, et al.
Indian J Med Res
. 2023 Jan;
156(2):191-197.
PMID: 36629179
Background & Objectives: In the current health system, cash incentives are given to accredited social health activists for referring women to public health facilities for specific maternal and child health...
6.
Pan D, Odorizzi P, Schoenichen A, Abdelghany M, Chen S, Osinusi A, et al.
Commun Med (Lond)
. 2023 Jan;
3(1):2.
PMID: 36596885
Background: Remdesivir (RDV) is an intravenous antiviral with activity against SARS-CoV-2 for treatment of hospitalized COVID-19 patients with moderate-to-severe disease. Biomarkers associated with clinical outcomes have been identified for COVID-19,...
7.
Feng J, Du Pont V, Babusis D, Gordon C, Tchesnokov E, Perry J, et al.
Molecules
. 2022 Jul;
27(13).
PMID: 35807457
The urgent response to the COVID-19 pandemic required accelerated evaluation of many approved drugs as potential antiviral agents against the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Using...
8.
Gottlieb R, Juneja K, Hill J
N Engl J Med
. 2022 Feb;
386(11):1094.
PMID: 35172053
No abstract available.
9.
Gottlieb R, Vaca C, Paredes R, Mera J, Webb B, Perez G, et al.
N Engl J Med
. 2021 Dec;
386(4):305-315.
PMID: 34937145
Background: Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk...
10.
Juneja K, Humeniuk R, Porter D, Cao H, Feng J
Antimicrob Agents Chemother
. 2021 Feb;
65(4).
PMID: 33558289
No abstract available.